Second-line treatment for mesothelioma is the therapy a patient receives after the first treatment stops controlling the cancer. A 2026 German study offers encouraging news on that question: standard chemotherapy still helped many pleural mesothelioma patients whose cancer grew after immunotherapy. That matters because doctors have had little real-world data on what to try next once first-line immunotherapy stops working.
At Throneberry Law Group, we follow treatment research closely because our clients and their families live with these decisions. Michael Throneberry lost his father-in-law to mesothelioma, and our firm has helped people with this disease for about two decades. Our mesothelioma treatment overview explains the main options, and this post covers what the new study adds. Treatment decisions belong to you and your oncologist, so bring these findings to your next appointment rather than acting on them alone.
What Did the German MesoNet Study Find
The study found that platinum chemotherapy combined with pemetrexed kept working for many patients after immunotherapy failed. Researchers at 12 German cancer centers reviewed records of 135 people with pleural mesothelioma who received nivolumab and ipilimumab as their first treatment. The results were published in the journal Clinical Lung Cancer by Shah and colleagues in 2026.
When the cancer progressed, 57 patients, or 42 percent, were healthy enough for a second treatment, and 41 of them received platinum chemotherapy plus pemetrexed. The National Cancer Institute lists both immunotherapy drugs used for advanced mesothelioma, nivolumab and ipilimumab, on its treatment page, and chemotherapy remains a standard option alongside them.
How Well Did Chemotherapy Work After Immunotherapy
Chemotherapy after immunotherapy produced meaningful disease control in this group. The researchers reported several outcomes for the 41 patients who received platinum and pemetrexed:
- Survival: Patients lived a median of 11.5 months after starting the second treatment.
- Time before progression: The cancer stayed under control for a median of 5.8 months.
- Disease control: About 72 percent of patients had disease control, meaning the cancer shrank or stopped growing during treatment.
- Tumor shrinkage: About 28 percent of patients had tumors that became smaller.
These numbers suggest that earlier immunotherapy did not prevent chemotherapy from working. Our chemotherapy for mesothelioma page explains how these drugs are given and what side effects to expect.
Why Early Treatment Planning Matters
The study also showed how quickly options can narrow. More than half of the original 135 patients never received a second treatment, and only 22 patients, about 16 percent of the group, reached a third. The researchers noted that disease progression and declining health often limit the chance for more therapy.
Planning Ahead With Your Oncologist
Those numbers are a reason to discuss future options before health worsens, not after. Because mesothelioma can progress fast, planning the next step while you are still strong enough to receive it can keep more doors open. Our post on the benefits of immunotherapy for mesothelioma covers the first-line side of that conversation.
Limits of the Study
The study has real limits. It reviewed existing medical records rather than assigning treatments in a randomized trial, and only 41 patients received the chemotherapy combination. Patients healthy enough for a second treatment may have been stronger than average to begin with. More research is needed to learn who benefits most and in what order treatments should be given.
How Treatment Costs Connect to Your Legal Options
Every additional line of treatment adds cost, travel, and time away from work. If asbestos exposure caused your mesothelioma, the companies responsible may be made to pay for that care. Our page on mesothelioma compensation explains what a claim can cover, including future medical expenses.
A diagnosis is also the moment to document your exposure history, because old records and witnesses fade with time. Our mesothelioma diagnosis page explains the medical records we need to begin.
Nationwide Mesothelioma Lawyers at Throneberry Law Group
Research like the MesoNet study gives families cautious hope, and we want our clients focused on their health while we handle the legal side. Throneberry Law Group investigates asbestos exposure, identifies the responsible companies, and pursues compensation that may cover treatment, including second-line and later therapies, for clients across the country.
If you or a family member is being treated for mesothelioma, we can review your situation at no cost and explain what a claim could mean for your family. Reach us through our contact form for a free consultation.
